Diabetic Retinopathy Market Size is expected to reach USD 14.2 billion by 2026; Rising Incidences of Diabetes Globally to Stimulate the Market Growth

The global Diabetic Retinopathy Market was valued at USD 10.1 billion in 2020 and is expected to reach USD 14.2 billion by 2026, exhibiting a CAGR of 5.8% during forecasted period 2020-2026. Global rise in incidences of diabetes coupled with vision concerns caused by prolonged diabetes are key factors contributing to the growth of Diabetic Retinopathy market. This comprehensive study on Diabetic Retinopathy identifies the current revenue size of the industry along with forecast estimation for next 6 years to 2026. The exhaustive research conducted by a team of life sciences domain experts and experienced market analysts studies the historical market scenario and evaluates the impact of COVID-19 on the segment growth and deviation analysis, enabling businesses to identify potential openings and recover from these unexpected alterations. The geographic analysis at regional and country level offers in-depth insights on potential growth regions, their market share and factors influencing the market development.

Diabetes Retinopathy: Disease Overview

Diabetic retinopathy is a complication of diabetes that causes damage to the blood vessels in the retina. Over time, high blood sugar level can cause swelling and blockage in the tiny blood vessels to the retina and may lead to the vision loss. The data from study conducted at CDC found high prevalence of the complication in U.S. population, affecting almost one third of adults over 40 years with diabetes. There are two types of diabetic retinopathy: early diabetic retinopathy and late diabetic retinopathy. The complications can develop in anyone with type 1 or type 2 diabetes and can be treated with medication, laser surgery, and vitrectomy. Anti-VEGF medication that includes Avastin, Eylea and Lucentis are the first line of therapy for the treatment and is given to reduce the swelling of the macula and improve vision.

Request for a Sample copy of this report @ https://www.icognitioninsights.com/product/diabetic-retinopathy-market-analysis/#1609849679664-70b4a1b3-fb5c

Market Driver and Restraint Analysis:

Rising Prevalence of Diabetes and Rewarding Opportunities for Biosimilars to Expand Market Size

Rising Prevalence of diabetes globally and growing vision related concerns in adults with diabetes are two prominent factors that will drive the growth of diabetic retinopathy segment. The CDC publication found that a total of 34.2 million people in U.S. are living with diabetes. Similar research by The British Diabetic Association indicates that more than 4.9 million people in UK have diabetes and the number may reach to 5.5 million by 2030. Additionally, deeper understanding of the disease and favorable conditions for the biosimilars entry may contribute to the overall segment growth.

Treatment Side Effects and Inadequate Diagnosis to Hamper the Growth

The complications and side effects of medications prescribed to minimize the effects of diabetic retinopathy is the key factor in restraining the market growth. According to National Health Service, UK (NHS), diabetic retinopathy treatment can cause blurred vision and aching or discomfort thereby leading to difficulty in perceiving colors. Furthermore, inadequate diabetic retinopathy treatment plans in low-income countries, lack of treatment awareness and dearth of qualified professionals in the emerging markets are expected to impede the market growth.

Market Share Analysis of Key Segments:

Established Medical Infrastructure and Increasing Number of People Living with Diabetes to Accelerate Growth in North America Region

North America accounted for the highest revenue share of 42.8% in 2020 and is expected to remain dominant during the forecast period to 2026. This is due to well-established medical infrastructure, rising number of people with diabetes and increasing awareness regarding availability of advanced options for treating diabetic retinopathy. Asia Pacific region is projected to show a significant CAGR over the forecast period owing to the rising incidences of geriatric population and escalating demand for advanced medication and treatment.

Proliferative Type Segment to witness fastest CAGR during the forecast period to 2026

The non-proliferative type segment accounted for the maximum revenue share in 2020 due to inadequate compliances for screening retinal disorders in diabetic patients. However, the proliferative segment is projected to grow at the highest CAGR during the forecast period owing to the increasing number of diabetes patients and high number of aging populations with proliferative retinopathy.

The Laser Surgery Management segment to show Highest CAGR during the forecast period to 2026

The anti-VEGF management segment held the highest revenue share in 2020 owing to broad application of drugs for early diagnosis and treatment of minor non-proliferative diabetic retinopathy and rapid recovery. However, in the long run, laser surgery segment is anticipated to exhibit highest CAGR during the forecast period owing to its improved treatment outcomes and technology advancements.

For a comprehensive analysis of the market, please visit @ https://www.icognitioninsights.com/product/diabetic-retinopathy-market-analysis/#Table-of-Contents1609137109204

Competitive Landscape Analysis:

This global report sheds light on key strategies and approaches adopted by the leading organizations to stay ahead of the competition and acquire maximum market stake.

List of Key Companies profiled in the Diabetic Retinopathy Market Report:

  • Kowa Group (Japan)
  • BCN Peptides (Spain)
  • Ampio Pharmaceuticals, Inc. (U.S.)
  • Alimera Sciences, Inc. (U.S.)
  • Glycadia Inc. (U.S)
  • Hoffmann-La Roche AG (Switzerland)
  • Oxurion (Belgium)
  • AbbVie Inc. (U.S.)
  • Regeneron Pharmaceuticals, Inc. (U.S.)
  • Bayer AG (Germany)
  • Novartis International AG (Switzerland)

Growth Strategies adopted by Key Players are focus on Geographic Expansion through Acquisitions and Technology Innovation

  • April 2021: Alimera Sciences, Inc. a biopharmaceutical company grants exclusive license of 0.19mg fluocinolone acetonide intravitreal implant to Ocumension. This acquisition will help Ocumension in developing and commercializing the product for the treatment of diabetic macular edema and other retina diseases in Greater China territory and other Western Pacific countries under Ocumension’s own distinct trademark. Alimera Sciences has received USD 20 Million from Ocumension Therapeutics. Through this opportunity Alimera looks to continue their strategy of geographic expansion reach their vision of creating a unique global company solely focused on retina specialists and their patient.
  • March 2021: Sankara Eye Foundation and Singapore-based Leben Care develops Intel powered retina risk assessment software called Netra.AI as a service platform in India that matches the accuracy of human doctors and reduces the screening burden on surgeons as it will be able to detect diabetic retinopathy (DR). By adopting Netra.AI, Sankara and Leben have leveraged the powerful functions of the Intel Xeon Scalable processor and integrated Intel Deep Learning (DL) Boost to accurately detect DR and achieve rapid treatment, effectively combating preventable visual impairment and blindness in patients with diabetes.

Interested in customizing this report, reach us @ https://www.icognitioninsights.com/inquire-before-buying/

The Global Diabetic Retinopathy market can be segmented into the following Categories:

  1. Diabetic Retinopathy Market, By Type (Revenue, USD Billion, 2018 – 2026)
    • Non-Proliferative
    • Proliferative
  2. Diabetic Retinopathy Market, By Management (Revenue, USD Billion, 2018 – 2026)
    • Intraocular Steroid Injection
    • Anti VEGF
    • Vitrectomy
    • Laser Surgery
  3. Diabetic Retinopathy Market, By Region (Revenue, USD Billion, 2018 – 2026)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Spain
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of APAC
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Rest of LATAM
      • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • Rest of MEA

Select User License and Express buy the full report @ Purchase Report: Checkout

Take a tour of our other trending reports:

Diabetic Foot Ulcer Market Analysis by Treatment (Wound Care Settings, Therapy Devices, Biologics), by Ulcer Type (Ischemic Ulcers, Neuropathic Ulcers, Neuro-ischemic Ulcers), and by Region – Forecast to 2026

Diabetes Monitoring Devices Market Analysis by Product (Continuous Monitoring, Self-Monitoring), by Distribution Channel (Hospital, Retail, Online), by End User (Hospitals, Homecare Setting, Diagnostic Centre), and by Region – Forecast to 2026

Drug Delivery Technologies Market Analysis by Route of Administration (Oral, Injectable, Topical, Ocular, Pulmonary, Nasal, Transmucosal, Implantable), by Application (Cancer, Autoimmune, Infectious, Cardiovascular, Respiratory, Diabetes), by End User, and by Region – Forecast to 2026

AI in Remote Patient Monitoring Market Analysis by Solution (Hardware, Software), by Technology (NLP, ML), by Product (Vital Sign Monitors, Special Monitors), by Application (Cancer, CVD, Diabetes), and by Region – Forecast to 2025

About iCognition Insights:

iCognition Insights is a global market research services firm, specialized in providing industry-standard syndicated reports and consulting services to global clients across life sciences and healthcare industry verticals. Our methodological research approach coupled with deep domain and analytical expertise opens the doors to the insights that really matter. Our reports are carefully packaged and published to offer reliable and latest industry insights, forecast and strategy inputs; helping our clients address major business objectives, from market understanding, penetration and entry strategies to product portfolio management and competitor analysis.

Contact Us:

iCognition Insights Pvt. Ltd.

No. 7, Sai Apt., Survey No. 67,

Tingre Nagar, Pune- 411032, India


US: +1 617 676 0160

APAC: +81 503 196 4844

Email: [email protected]

Website: https://www.icognitioninsights.com/

LinkedIn | Twitter | Blogs

Leave a Comment

Your email address will not be published. Required fields are marked *